Clinical trials
Lung Cancer (Suspected or Confirmed) clinical trials
Below are recruiting lung cancer (suspected or confirmed) clinical trials, each written for real people, not researchers. We’re tracking 6,580 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06826079RecruitingPhase 2
Sorbitol plus chemo and immunotherapy for advanced gastric cancer
This trial tests adding sorbitol to standard chemotherapy and an immunotherapy drug (tirellizumab) for people with locally advanced stomach cancer. The goal is to see if this combination is safe and helps shrink tumors before surgery.
Wuhan, HubeiAges 18–70 - NCT05894824RecruitingPhase 1/Phase 2
T-DXd with ramucirumab for HER2-low stomach and GEJ cancer
This trial studies T-DXd given with ramucirumab to treat stomach (gastric) or stomach–esophagus junction (GEJ) cancer that has spread or is locally advanced and is “HER2-low.” It’s mainly to test safety and early effectiveness in people whose cancer continued after first-line treatment.
Seoul, SeoulAges 19 years+ - NCT06279351RecruitingPhase 2
Thalidomide plus standard chemo and cetuximab for left-sided colon cancer
This trial tests whether adding the drug thalidomide to standard chemotherapy plus cetuximab can work better for people with advanced left-sided colorectal cancer that hasn't been treated before. If you have a specific gene type (RAS/BRAF wild-type) and are in generally good health, this study may be an option.
Chongqing, Chongqing MunicipalityAges 18–75 - NCT06817525RecruitingPhase 2
Chemo and immunotherapy before surgery for early triple-negative breast cancer
This trial tests whether a combination of chemotherapy drugs (nab-paclitaxel and carboplatin) plus an immunotherapy drug (PD1 inhibitor) given before surgery can help treat early-stage triple-negative breast cancer. It aims to improve outcomes by using these treatments before the main surgery.
Zhengzhou, HenanAges 18–65 - NCT06819007RecruitingPhase 3
Study of trastuzumab deruxtecan plus bevacizumab for HER2-positive ovarian cancer
This trial tests whether adding trastuzumab deruxtecan to standard maintenance therapy with bevacizumab works better than bevacizumab alone for people with advanced ovarian cancer that has the HER2 protein. It is for those who have finished initial chemotherapy plus bevacizumab and are now starting maintenance treatment.
Burbank, CaliforniaAges 18 years+ - NCT06817954Recruiting
Breast reconstruction after mastectomy for breast cancer
This trial tests how safe and effective it is to remove the breast (mastectomy) and rebuild it right away during the same surgery. It is for women with early-stage breast cancer who want reconstruction instead of breast-sparing surgery.
Nanjing, JiangsuAges 18–75 - NCT06819228RecruitingPhase 1
Lighted antibody imaging in head and neck cancer surgery
This trial tests a special fluorescent dye attached to panitumumab, a cancer-targeting antibody, to help surgeons see tumor tissue more clearly during head and neck cancer surgery. The goal is to improve removal of all cancer cells while sparing healthy tissue.
Nashville, TennesseeAges 18 years+ - NCT06824688Recruiting
Comparing robotic surgery types for rectal cancer
This trial compares two robotic surgery methods for rectal cancer: using one small incision (single-port) versus several small incisions (multi-port). The goal is to see which approach offers better outcomes while preserving the sphincter (the muscle that controls bowel movements).
ChongqingAges 18 years+ - NCT05862064RecruitingPhase 3
Adding an immune drug and anti-blood-vessel treatment to chemo
This study tests whether adding an immune therapy (a PD-1 antibody) plus a blood-vessel–blocking treatment to standard chemo improves outcomes for people with surgically treated triple-negative breast cancer. Everyone gets chemotherapy, but some will also get the added drugs to try to reduce cancer coming back.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06807359RecruitingPhase 1/Phase 2
Light-activated therapy for localized prostate cancer
This trial uses a special light-activated drug (photodynamic therapy) to treat prostate cancer that is still confined to the prostate. It aims to destroy the cancer while sparing healthy tissue, and may be an option for people with intermediate-risk prostate cancer who have not had other treatments.
New York, New YorkAges 18 years+ - NCT06803771Recruiting
Checking pancreas health after a new diabetes diagnosis
This study looks at people recently diagnosed with type 2 diabetes to check their pancreas health using blood tests and scans. The goal is to find early signs of pancreatic issues, which might help catch problems sooner.
Sandbach, CheshireAges 50–84 - NCT06329973RecruitingPhase 1/Phase 2
Fruquintinib, sintilimab, and chemo for stomach cancer
This trial tests a combination of three drugs (fruquintinib, sintilimab, and CAPEOX chemotherapy) as a first treatment for advanced stomach or gastroesophageal cancer. The goal is to see if this combination helps slow or shrink the tumor.
Zhengzhou, HenanAges 18–75 - NCT06793917RecruitingPhase 3
Immunotherapy plus chemo vs. chemo alone for advanced stomach cancer
This trial compares two types of chemotherapy with or without an immunotherapy drug (tislelizumab) for advanced stomach or gastroesophageal junction cancer. It aims to see which combination works better and has fewer side effects.
Fuzhou, FujianAges 18–70 - NCT06799637RecruitingPhase 1/Phase 2
Study of XNW28012 for advanced solid tumors
This trial tests a new drug called XNW28012 for people with advanced solid tumors that have not responded to or caused side effects from standard treatments. It aims to see if the drug can shrink tumors or slow their growth.
Hefei, AnhuiAges 18 years+ - NCT06800313RecruitingPhase 1/Phase 2
A study of HLD-0915 for metastatic prostate cancer
This trial tests a new drug called HLD-0915 in men with prostate cancer that has spread. It aims to see how well the drug works and if it's safe.
Colorado Springs, ColoradoAges 18 years+ - NCT06797635RecruitingPhase 2
Study of Patritumab Deruxtecan and Pembrolizumab for High-Risk Early Breast Cancer
This trial tests a combination of targeted therapies (patritumab deruxtecan plus pembrolizumab) along with other anticancer drugs for people with a high-risk type of early-stage breast cancer that is either triple-negative or has very low hormone receptors and is HER2-negative. The goal is to see if this approach can help prevent the cancer from coming back.
Santa Monica, CaliforniaAges 18 years+ - NCT06801665RecruitingPhase 2
Combination therapy for advanced colorectal cancer with liver spread
This trial tests a new combination of treatments for advanced colorectal cancer that has spread to the liver. It aims to see if this combination can shrink tumors and help patients live longer.
ChangzhouAges 18–75 - NCT06796764Recruiting
Breathing tube safety during endoscopy in people with obesity
This trial tests a special breathing tube to see if it can prevent low oxygen levels during sedated endoscopy in people with obesity. If you are scheduled for both an upper endoscopy and colonoscopy, this study may help make the procedure safer.
Hangzhou, ZhejiangAges 18–70 - NCT06059469RecruitingPhase 2
PSMA scan for advanced triple-negative breast cancer
This trial uses a special scan (PSMA-PET/CT) to see if your breast cancer makes a protein called PSMA. The results might help guide your future treatment.
BrusselsAges 18 years+ - NCT06783348RecruitingPhase 2
Radioactive treatment for advanced kidney cancer
This trial tests a radioactive treatment (called radiopharmaceutical) that targets a protein called PSMA on kidney cancer cells. It is for people with advanced clear cell kidney cancer that has already been treated with immunotherapy and targeted therapy.
CaenAges 18–100 - NCT06790693RecruitingPhase 3
Inavolisib plus hormone therapy for advanced breast cancer
This trial tests a new targeted therapy, inavolisib, combined with standard hormone therapy and a CDK4/6 inhibitor for people with a specific genetic mutation (PIK3CA) in their hormone receptor-positive, HER2-negative advanced breast cancer that has not been treated before. It compares this combination to a placebo plus the same standard treatments.
Goodyear, ArizonaAges 18 years+ - NCT06785636RecruitingPhase 1/Phase 2
New drug combination for advanced prostate cancer
This study tests a new drug (pocenbrodib) alone or combined with another hormone therapy (darolutamide) for men with advanced prostate cancer that has spread. It is for those who have already tried Pluvicto and one other hormone therapy, but not yet chemotherapy.
Fountain Valley, CaliforniaAges 18 years+ - NCT06792695RecruitingPhase 2
Study of new treatments for colorectal cancer
This trial tests new treatment combinations for colorectal cancer that has spread (metastatic). It is for people whose cancer is mismatch repair proficient (pMMR) or microsatellite stable (MSS) and who have not had previous treatment for metastatic disease.
Scottsdale, ArizonaAges 18–130 - NCT06788171RecruitingPhase 2
Combined therapy for colorectal cancer with liver spread
This trial tests a new combination of treatments for colorectal cancer that has spread to the liver. It combines a special type of radiation therapy (called PULSAR) with immunotherapy and chemotherapy plus a drug that targets blood vessels, to see if it helps shrink tumors and improve outcomes.
Fuzhou, FujianAges 18–75
Hear when a new Lung Cancer (Suspected or Confirmed) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lung cancer (suspected or confirmed)?
- Yes. Clin2 currently lists 6,580 recruiting lung cancer (suspected or confirmed) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lung cancer (suspected or confirmed) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lung cancer (suspected or confirmed) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.